Signal
Coultreon Biopharma raises $125 million to advance immune drug licensed from Galapagos
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-28 11:08 UTCUpdated 2026-04-28 12:33 UTC
rss
biotechfundingdrug_developmentimmunologyclinical_trials
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Coultreon Biopharma, formerly Onco3R Therapeutics, secured $125 million in Series A funding to develop an oral immune drug licensed from Galapagos. The Belgian biotech, launched in 2025 to develop deprioritized Galapagos assets, aims to test the drug's potential across multiple immunological diseases.
Entities
Coultreon BiopharmaOnco3R TherapeuticsGalapagosNovo HoldingsRegeneron Ventures
Score total
0.98
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Coultreon recently rebranded and secured significant capital to accelerate clinical testing.
- The move follows Galapagos deprioritizing the asset, creating an opportunity for focused development.
- The immunology drug candidate could address unmet needs across multiple diseases, driving timely interest.
Why it matters
- The funding enables advancement of a potentially impactful immune drug previously shelved by a major biotech.
- It highlights strategic asset redeployment in biotech, rescuing promising candidates for further development.
- Support from prominent investors like Novo Holdings and Regeneron underscores confidence in the drug's potential.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Coultreon Biopharma raised $125 million in Series A funding to develop an oral immune drug licensed from Galapagos.
- The drug candidate was deprioritized by Galapagos and is now being advanced by Coultreon across multiple immunological diseases.
How sources frame it
- Coultreon Biopharma And Its Investors: supportive
Consolidated two reports into a clear narrative on Coultreon's funding and drug development progress.
All evidence
All evidence
Coultreon banks $125M to support testing of former Galapagos immune drug
BioPharma Dive · biopharmadive.com · 2026-04-28 12:33 UTC
After launching in 2025 as a refuge for shipwrecked assets from Galapagos, Onco3R Therapeutics is rebranding as Coultreon Biopharma and filling its treasure chest with a $125 mi...
Fierce Biotech · fiercebiotech.com · 2026-04-28 11:08 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)